Company
Austin
Every investor coverage indicates participated in a round The University of Texas at Austin raised.
Companies The University of Texas at Austin acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Ilya Finkelstein | Associate Professor | Brandon BioCatalyst portfolio, Brandon Capital portfolio |
| Jennifer Maynard | Professor | Brandon BioCatalyst portfolio, Brandon Capital portfolio |
| Jason McLellan | Professor of Molecular Biosciences and Welch Chair in Chemistry | Brandon BioCatalyst portfolio, Brandon Capital portfolio |
Stories naming The University of Texas at Austin. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Vaxxas reports encouraging interim Phase I results for its needle-free microarray-patch COVID-19 vaccine, with strong antibody responses and no serious adverse events, ahead of planned regulatory applications in Australia and the US.
Vaxxas has begun an Australian Phase I trial of its needle-free COVID-19 vaccine patch, built on a University of Texas at Austin candidate; the article also recalls the company's early financings led by OneVentures.
Vaxxas has begun an Australian Phase I trial of its needle-free COVID-19 vaccine patch; the article also recalls the company's founding financing led by OneVentures with Brandon Capital and other co-investors.
Vaxxas has begun a phase one trial in Australia of its needle-free COVID-19 vaccine patch. The Brisbane company, backed by OneVentures, Brandon Capital and others, has hired Scott Fry from Ellume as COO.
Brisbane biotech Vaxxas has begun human testing of its microneedle patch for COVID-19 vaccination and plans a phase two study; the venture-backed company has raised over $66 million.